- Home
- BTO vs SYRE Comparison
BTO vs SYRE Comparison
Compare BTO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTO | SYRE |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.2M | 2.6B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BTO | SYRE |
|---|---|---|
| Price | $38.92 | $37.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $56.50 |
| AVG Volume (30 Days) | 54.2K | ★ 559.5K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 9.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.95 | $10.91 |
| 52 Week High | $32.81 | $35.58 |
Technical Indicators
Market Signals| Indicator | BTO | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 63.96 |
| Support Level | $38.13 | $32.35 |
| Resistance Level | $39.85 | $35.58 |
| Average True Range (ATR) | 0.73 | 1.83 |
| MACD | -0.03 | 0.22 |
| Stochastic Oscillator | 52.46 | 92.11 |
Price Performance
Historical ComparisonAbout BTO John Hancock Financial Opportunities Fund
John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.